155 related articles for article (PubMed ID: 22630094)
1. Intravitreal bevacizumab in central serous chorioretinopathy.
Jamil AZ; Rahman FU; Iqbal K; Ansari HM; Iqbal W; Mirza KA
J Coll Physicians Surg Pak; 2012 Jun; 22(6):363-6. PubMed ID: 22630094
[TBL] [Abstract][Full Text] [Related]
2. The efficacy of intravitreal bevacizumab for acute central serous chorioretinopathy.
Aydin E
J Ocul Pharmacol Ther; 2013 Feb; 29(1):10-3. PubMed ID: 22925113
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal bevacizumab to treat acute central serous chorioretinopathy: short-term effect.
Seong HK; Bae JH; Kim ES; Han JR; Nam WH; Kim HK
Ophthalmologica; 2009; 223(5):343-7. PubMed ID: 19521133
[TBL] [Abstract][Full Text] [Related]
4. [Recurrent and chronic central serous chorioretinopathy. Retina thickness evaluation one month after intravitreal bevacizumab injection].
Gregori-Gisbert I; Aguirre-Balsalobre F; García-Sánchez J; León-Salvatierra G; Mengual-Verdú E; Hueso-Abancéns JR
Arch Soc Esp Oftalmol; 2011 Dec; 86(12):407-11. PubMed ID: 22117740
[TBL] [Abstract][Full Text] [Related]
5. Visual results following intravitreal Bevacizumab in neovascular age-related macular degeneration.
Iqbal K; Baig J; Jamil AZ; Jamil H; Mirza K; Khan T
J Coll Physicians Surg Pak; 2011 Sep; 21(9):535-8. PubMed ID: 21914409
[TBL] [Abstract][Full Text] [Related]
6. The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
Lee ST; Adelman RA
J Ocul Pharmacol Ther; 2011 Dec; 27(6):611-4. PubMed ID: 21810026
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab injection for central serous chorioretinopathy.
Lim SJ; Roh MI; Kwon OW
Retina; 2010 Jan; 30(1):100-6. PubMed ID: 20010322
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study.
Artunay O; Yuzbasioglu E; Rasier R; Sengul A; Bahcecioglu H
Curr Eye Res; 2010 Feb; 35(2):91-8. PubMed ID: 20136418
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab for exudative age-related macular degeneration in clinical practice.
Jonas JB; Tao Y; Schlichtenbrede FC
J Ocul Pharmacol Ther; 2011 Oct; 27(5):467-70. PubMed ID: 21682590
[TBL] [Abstract][Full Text] [Related]
11. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edema.
Solaiman KA; Diab MM; Abo-Elenin M
Retina; 2010; 30(10):1638-45. PubMed ID: 20838357
[TBL] [Abstract][Full Text] [Related]
13. Treatment of serous macular detachment associated with circumscribed choroidal hemangioma.
Kwon HJ; Kim M; Lee CS; Lee SC
Am J Ophthalmol; 2012 Jul; 154(1):137-145.e1. PubMed ID: 22465363
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
15. Bilateral intravitreal bevacizumab injection for exudative age-related macular degeneration: effect of baseline visual acuity.
Jonas JB; Tao Y; Rensch F
J Ocul Pharmacol Ther; 2011 Aug; 27(4):401-5. PubMed ID: 21810019
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study.
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Retina; 2007 Feb; 27(2):141-9. PubMed ID: 17290194
[TBL] [Abstract][Full Text] [Related]
17. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up.
Wu L; Arevalo JF; Roca JA; Maia M; Berrocal MH; Rodriguez FJ; Evans T; Costa RA; Cardillo J;
Retina; 2008 Feb; 28(2):212-9. PubMed ID: 18301025
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal injection of 2.5 mg bevacizumab for treatment of myopic choroidal neovascularization in treatment-naive cases: a 2-year follow-up.
Chen CH; Wu PC; Chen YJ; Liu YC; Kuo HK
J Ocul Pharmacol Ther; 2011 Aug; 27(4):395-400. PubMed ID: 21770740
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin.
Chan WM; Lai TY; Liu DT; Lam DS
Am J Ophthalmol; 2007 Jun; 143(6):977-983. PubMed ID: 17459318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
